

Accuray Incorporated

(Nasdaq: ARAY)

*J.P. Morgan Healthcare Conference
Investor Presentation
January 15, 2020*

AGENDA

1. **Accuray's Inflection Point**
 - Line of Sight to Accelerating & Sustainable Revenue and Profit Growth
2. **China**
 - Unprecedented Growth Catalyst & Accuray's Differentiated Strategy
3. **Accuray's Differentiated System Platforms**
4. **Accuray Portfolio For Value-Based Care**
5. **Summary: Accuray's Accelerating Growth Drivers**



FORWARD-LOOKING STATEMENTS

This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing

Safe Harbor Statement

Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation relate, but are not limited, to: our growth drivers and strategic priorities; our ability to continue to innovate; our ability to expand the addressable market of our products; our expectations regarding CMS’ proposed Alternative Payment Model as well as reimbursement trends and our ability to capitalize on the same; expectations regarding growth in the radiation therapy market; expectations regarding system revenue contributions from China; expectations related to the market opportunity in China and its ability to grow our business, drive sustainable revenue growth and increase operating leverage; our future results of operations and financial position, including management’s expectations regarding revenue and adjusted EBITDA; expectations regarding new product enhancements, including with respect to Synchrony; expectations regarding product replacement cycle; the success of our current and future products and their impact on our business; our belief that our products offer clinicians and patients significant benefits over other radiation therapy systems in the market; and our expectations regarding order growth and long-term market expansion opportunities. Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “may,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. These risks and uncertainties include, but are not limited to: our ability to achieve widespread market acceptance of our products, including new product and software offerings; our ability to develop new products or enhance existing products to meet customers’ needs and compete favorably in the market; our ability to effectively integrate and execute the joint venture; our ability to realize the expected benefits of the joint venture; risks and uncertainties related to future Type A and B license announcements in China; risks inherent in international operations; our ability to effectively manage our growth; our ability to maintain or increase our gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; our ability to meet the covenants under our credit facilities; our ability to convert backlog to revenue; and other risks identified under the heading “Risk Factors” in our quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 6, 2019, and as updated periodically with our other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

Non-GAAP Financial Measures

This presentation also contains non-GAAP financial measures. Management believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. Additionally, these non-GAAP financial measures assist management in analyzing future trends, making strategic and business decisions, and establishing internal budgets and forecasts. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure is provided in the appendices.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company’s consolidated financial statements prepared in accordance with GAAP.



ACCURAY'S INFLECTION POINT

LINE OF SIGHT TO ACCELERATING & SUSTAINABLE REVENUE AND PROFIT GROWTH

P&L Trend


Revenue



Adj.
EBITDA⁽¹⁾



Operating
Income



FY21- FY23
EXPECTED
REVENUE
CAGR 8%-12%

OPERATING
LEVERAGE
EXPECTED
TO DRIVE
FASTER
PROFIT
GROWTH

REVENUE GROWTH DRIVERS

FY21- FY22

50 CHINA TYPE A LICENSES
AWARDED PROVIDE HIGH VISIBILITY
TO 8%-12% ANNUAL REVENUE
GROWTH

FY22 – FY23

EXPECTED LAUNCH OF CHINA JV
LINAC (TYPE B) TO DRIVE
SUSTAINABLE 8%-12% ANNUAL
REVENUE GROWTH



(1) Adjusted EBITDA is a non-GAAP financial measure. See the appendix for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure.

(2) Represents a mid-point of FY20 Guidance as presented on Q1 earnings release dated October 29, 2019. Prior guidance has not been updated and this is not intended as a reaffirmation of prior guidance.

(3) Expected operating income for Fiscal 2020 as of October 29, 2019.

ENHANCED SHAREHOLDER VALUE

ACCELERATING REVENUE GROWTH

8%-12%

Expected Revenue CAGR FY21-23

HIGH RECURRING REVENUE

53%

Recurring Service Revenue for FY2019
as a % of Total FY 2019 Revenue

ORDER GROWTH

>15%⁽¹⁾

TTM Order Growth

CHINA

~\$115M⁽²⁾

Expected Incremental System
Revenue Contribution From China
over 24 to 30 Months starting in
Q4'FY20

MARGIN AND PROFIT EXPANSION

Operating Leverage
Expected to Drive Faster Operating
Income & Adjusted EBITDA
Expansion

VALUATION

>75%⁽³⁾

EV/Sales Trading Discount to
Comparable Group



(1) Trailing twelve months as of September 30, 2019.

(2) Estimated system revenue value of China Type A licenses granted for Accuray systems as of October 9, 2019.

(3) Data as of January 8, 2020. Refer to Appendix C.

CHINA: UNPRECEDENTED GROWTH CATALYST

China Expected Cancer Incidence

Annual New
Diagnosed ⁽¹⁾



12,000




/day

4.3M (2.5x the amount in the U.S.)

China's lack of access to Radiotherapy: Linac Installed Base by Country

Significant
Gap ⁽¹⁾



CHINA QUOTA SYSTEM

OCTOBER 2018 QUOTA ANNOUNCEMENT PROVIDES VISIBILITY ON MARKET OPPORTUNITY

QUOTA TYPE	ACCURAY PRODUCT	ACCURAY SUCCESS RATE
TYPE A “PREMIUM” 188	Radixact®	50 OUT OF 58 ⁽¹⁾ 86% of Type A licenses awarded to Accuray systems in the first round
	Tomo HD-A™ & HD®	
	CyberKnife®	
TYPE B “CORE” 1,208	Tomo H®	TBD
	New JV Linac ⁽²⁾	



(1) Represents the number of China Type A licenses granted for Accuray systems as of October 9, 2019.

(2) Under development and not yet available for sale.

CHINA JOINT VENTURE

ACCURAY'S DIFFERENTIATED STRATEGY

"MADE IN CHINA 2025" INITIATIVE

A locally branded and manufactured product well aligned with local policies

MARKET ACCESS

Existing sales infrastructure and access to hospitals

UNIQUE POSITIONING

Only company in market segment with a local Chinese partner

EXPANDS TYPE B OPPORTUNITY

Quickly expands China commercial coverage to maximize Type B sales



JV PARTNER



China Isotope & Radiation Corporation

- 25% of CIRC shares listed on the Hong Kong Stock exchange; market capitalization of HKD 6.5 billion⁽¹⁾
- Controlled by China National Nuclear Corporation ("CNNC"), a central State-Owned Entity ("SOE")
- The leading company in the field of isotope and irradiation technology applications in China
- The largest manufacturer of imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers and radioactive source products in China
- Nationwide sales network covering 31 provinces and more than 10,000 hospitals and other medical institutions
- Production facilities in 11 locations

(1) Market capitalization as of January 6, 2020

GLOBAL RADIATION THERAPY MARKET

GROWING ADDRESSABLE MARKET

18 MILLION



New Cases Of Cancer
Worldwide In 2018



50-60%



Of Cancer Patients
Worldwide Would Benefit
From Radiation Therapy



30%



Currently Receive
Radiation Therapy



+150%



Expected Increase In
Number Of Patients
Receiving Radiation
Therapy By 2035



+7,700



Number Of New Linacs Needed
To Meet Expected Demand For
Radiation Therapy in 2035



21,800*



Total Number Of Linacs
Needed By 2035



<https://www.who.int/news-room/fact-sheets/detail/cancer>

The Lancet Oncology Commission – "Expanding Global Access to Radiotherapy, Volume 16 September 2015 Edition
Radiotherapy in Cancer Care: Facing the Global Challenge, IAEA 2017


*21,800 includes 14,100 expected replacement systems and 7,700 new systems

ACCURAYS DIFFERENTIATED PLATFORMS

Accuray Develops, Manufactures And Sells Radiation Therapy Systems That Make Cancer Treatments Shorter, Safer, Personalized And More Effective.



 **CyberKnife®**
ACCURAY®



Radixact®
TomoTherapy®

CyberKnife® System: Unique Robotic Non-Coplanar Delivery

Submillimeter precision, from head to toe

PRECISE

- **Synchrony** - enables real-time tumor tracking and beam adjustment to continually and efficiently deliver dose to moving targets
- **Robotic** - allows a range of delivery angles with submillimeter precision, enabling safe dose escalation to tumors while minimizing dose to sensitive, surrounding tissue

FAST

- **VOLO** - reduces plan optimization time and delivery time, enabling stereotactic treatments in conventional 15 to 20 minute time slots

ECONOMICAL

- **Efficiency** – Hypofractionation delivers high dose treatments in fewer fractions, benefitting patients, clinical providers, and payors alike

PROVEN

- **Versatility** – supported by years of clinical evidence across a range of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) indications



Radixact®: Versatile Workhorse System

Next Generation TomoTherapy® System

PRECISE

- **Synchrony** - enables real-time tumor tracking and beam adjustment to continually and efficiently deliver dose to moving targets
- **Helical Delivery** - allows selection amongst thousands of tiny beamlets, only those required to paint dose where needed while minimizing dose to normal, healthy tissue

FAST

- **Throughput** – Speed and throughput improvements capable of supporting busiest clinics, while also treating the most challenging cases

ADAPTIVE

- **PreciseART** - measures adherence to original treatment plan objectives, and empowers clinicians to easily make delivery adjustments when required

UPGRADABLE

- **Architecture** – Product design supports easily upgradable innovation additions



200+ Orders since launch

~ 60% Orders Single/Dual Vaults



INSTALLED BASE REPLACEMENT OPPORTUNITY

INSTALLED BASE

926

Total Accuray systems installed through Sep. 2019

AGE

48%


Of installed Accuray systems over 8 years old leading to significant replacement opportunities over coming years

TRADE-IN AGE

10 Yrs

Average trade in age of Accuray systems over last 5 years

GEOGRAPHIC BREAKDOWN OF PRIMARY REPLACEMENT OPPORTUNITY



■ Americas ■ ROW



ACCURAY POISED TO BENEFIT FROM VALUE-BASED CARE

ACCURAY SYSTEMS DELIVER HYPOFRACTIONATED TREATMENTS SAFELY AND EFFICIENTLY

BREAST, LUNG, PROSTATE PROCEDURES REPRESENT ALMOST 60% OF ALL MEDICARE CLAIMS ⁽¹⁾

SYNCHRONY™



ACCURAY'S SYNCHRONY™ TECHNOLOGY PROVIDES MEANINGFUL BENEFIT FOR ALL 3 OF THESE PROCEDURES

PROSTATE REIMBURSEMENT



BASED ON CURRENT RATE PROPOSAL, PROSTATE TREATMENT LOOKS LIKE THE BIG WINNER IN RATE UPLIFT

CYBERKNIFE®



CYBERKNIFE® IS UNIQUELY POSITIONED FOR PRECISE, EFFICIENT, PROSTATE TREATMENTS

RADIXACT®



ACCURAY'S WORKHORSE PRODUCT IS NOW CAPABLE OF DELIVERING PRECISE HYPOFRACTIONATED TREATMENT WITH SYNCHRONY™

LONG TERM CLINICAL DATA



ACCURAY IS ONLY RT PLAYER WITH DEVICE SPECIFIC, MULTI-CENTER, PROSTATE SBRT CLINICAL DATA WITH LONG TERM FOLLOW UP




⁽¹⁾ United States Department of Health and Human Services REPORT TO CONGRESS: Episodic Alternative Payment Model for Radiation Therapy Services November 2017

CMS PROPOSED APM DRIVES VALUE-BASED CARE

ACCURAY PORTFOLIO WELL-POSITIONED TO SUPPORT PROPOSED ALTERNATIVE PAYMENT MODEL (APM)

A DRAMATIC REDUCTION IN CANCER TREATMENT TIMES


Hypofractionation typically reduces treatment times dramatically for a number of different indications:



ACCURAY SYNCHRONY

COMPETITIVE ADVANTAGE SUPPORTS VALUE-BASED CARE

- ✓ Only solution for true motion tracking (bringing the beam to the tumor)
- ✓ Enables tighter dosing margins, minimizing dose to healthy tissues and OAR
- ✓ Accurate, precise and efficient



**Synchrony for Radixact System introduced at
ASTRO 2019**

“Synchrony is the major advantage Accuray has over competing systems especially in the treatment of moving targets...”

Jonathan Haas
NYU Winthrop

CYBERKNIFE PROSTATE STUDY

THE PACE-B TRIAL: ACCUTE TOXICITY RESULTS

- ▶ Level 1 evidence study designed to determine non-inferiority of ultra-hypofractionated SBRT over conventionally fractionated or moderately hypofractionated radiotherapy in the treatment of low- and intermediate-risk prostate cancer
- ▶ Included 874 patients from 37 centers in 3 countries
- ▶ First demonstration that 5-fraction SBRT prostate treatment for low- and intermediate-risk cancer is as safe as the standard of care
- ▶ Preliminary data show SBRT treatments on CyberKnife resulted in statistically significantly fewer grade 2 and higher acute urinary toxicity than on conventional linac – 12.4% vs 30.6% (a 2.5-fold difference)



CyberKnife allows patients to receive higher dose and shorter treatment regimens with lowered risk of greater toxicity or incidence of side effects

The Lancet Oncology, September 17, 2019; "Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial" Douglas H Brand*, Alison C Tree*, Peter Ostler, Hans van der Voet, Andrew Loblaw, William Chu, Daniel Ford, Shaun Tolan, Sunil Jain, Alexander Martin, John Staffurth, Philip Camilleri, Kran Kancherla, John Frew, Andrew Chan, Ian S Dayes, Daniel Henderson, Stephanie Brown, Clare Cruickshank, Stephanie Burnett, Aileen Duffton, Clare Griffin, Victoria Hinder, Kirsty Morrison, Olivia Naismith, Emma Hall, Nicholas van As, on behalf of the PACE Trial Investigators

Disclaimer: This presentation includes summaries of "Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial". Such summaries do not purport to be complete and are subject to, and qualified in their entirety by, reference to the text of "Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial". Such summaries are given as of September 23rd, 2019 and we undertake no obligation to update for any changes subsequent to such date.

SUMMARY: ACCURAY'S ACCELERATING GROWTH DRIVERS

CHINA

- ▶ Significantly underserved market for radiation therapy with high growth expected over the next 10-15 years
- ▶ Accuray has the right product portfolio for China: Accuray systems named in 50 out of 58 Type A licenses awarded in October 2019
- ▶ Highly differentiated strategy with a local JV partner to capitalize on Type B system opportunity

+

VALUE-BASED CARE

- ▶ CMS Proposed Alternative Payment Model (RO-APM) will drive SBRT and hypofractionated treatment
- ▶ Accuray portfolio safely and efficiently delivers hypofractionation for the value-based care environment
- ▶ Accuray is the only RT solution provider with device specific clinical data

+

REPLACEMENT CYCLE

- ▶ Aging installed base creates above average replacement cycle cadence over the next 36 months
- ▶ 48% of existing installed base is over 8 years old with typical replacement cycles occurring around 10 years

=

**A LINE OF SIGHT TO
8%-12% REVENUE
CAGR FOR FY21-FY23**



**MARGIN & CASH FLOW
EXPANSION**

**ACCURAY HAS NEVER BEEN BETTER
POSITIONED!!**

APPENDIX

APPENDIX A

Reconciliation of GAAP Net Loss to Adjusted EBITDA (FY'20 Guidance)

Numbers in 000's	FY20 Guidance Mid-Point
GAAP Net Loss	\$ (15,500)
Depreciation and Amortization (a)	7,600
Stock-based Comp	12,100
Interest Expense, Net (b)	15,400
Provision for Income Taxes	1,900
Adjusted EBITDA	\$ 21,500

- (a) Consists of depreciation, primarily on property and equipment as well as amortization of intangibles.
(b) Consists primarily of interest expense associated with our outstanding debt.

APPENDIX B

Reconciliation of GAAP Net Loss to Adjusted EBITDA (FY'17 – FY'19)

Numbers in 000's	FY'17	FY'18	FY'19
GAAP Net Loss	\$ (29,579)	\$ (23,899)	\$ (16,430)
Depreciation and Amortization (a)	18,041	9,732	8,266
Stock-based Comp	13,629	12,288	10,601
Impairment charge (b)	-	-	3,707
Cost initiative (c)	-	-	1,509
Gain on lease termination (d)	-	-	(1,007)
Interest Expense, Net (e)	17,260	18,088	15,015
Provision for Income Taxes	1,038	878	2,086
Adjusted EBITDA	\$ 20,389	\$ 17,087	\$ 23,747

- (a) Consists of depreciation, primarily on property and equipment as well as amortization of intangibles.
 (b) Consists of a one-time accounts receivable impairment charge related to one customer recorded in the first quarter of 2019.
 (c) Consists of costs associated with a staff reduction recorded in the second and fourth quarters of 2019.
 (d) Consists of non-cash reversal of deferred rent related to a facility lease that was terminated.
 (e) Consists primarily of interest expense associated with our outstanding debt.

APPENDIX C

EV/Sales Trading Discount to Comparable Group

As of January 8, 2020

Ticker	Company	Stock Price	Shares Outstanding	Market Cap	Cash	Debt	Enterprise Value	SALES (TTM)	EV/SALES (TTM)
ARRAY	Accuray Incorporated	\$2.65	89	\$236	\$87	\$188	\$338	\$413	0.82
Ticker	Company	Stock Price	Shares Outstanding	Market Cap	Cash	Debt	Enterprise Value	SALES (TTM)	EV/SALES (TTM)
VAR	Varian Medical Systems, Inc.	\$146.00	91	\$13,271	\$531	\$410	\$13,150	\$3,225	4.08
VRAY	ViewRay, Inc.	\$3.81	147	\$561	\$242	\$55	\$375	\$92	4.07
EKTAY	Elekta	\$12.31	382	\$4,703	\$315	\$325	\$4,713	\$1,485	3.17
								Peer Group Average	3.77

Discount to Radiation Therapy
Peer Group

-78.31%

